Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma

Nuvectis Pharma, Inc. announced that NXP800 was granted Orphan Drug Designation by the US FDA for the treatment of cholangiocarcinoma.